Company research
SciSparc Ltd.
CIK 1611746Updated Sep 24, 2026
SecuritySPRC · NASDAQ · equity
Name history
SciSparc Ltd./ADR · through Aug 27, 2021Therapix Biosciences Ltd. · through Jan 28, 2021
SPRC price & chart
Loading TradingView…
NASDAQ:SPRC on TradingView ↗About the company
The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
In the news
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company ↗
SEC disclosures
SciSparc Ltd. IPO declared effective by SEC ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -7,472,000Source | -5,883,000Source | -2,592,000Source | -5,789,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 12,000Source | 55,000Source | 3,000Source | 170,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 25,000Source | -397,000Source | — | 353,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 569,000Source | 196,000Source | — | 43,000Source |
| GeneralAndAdministrativeExpenseUSD | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 8,000Source | 7,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 54,000Source | 47,000Source | — | — |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 9,005,000Source | 7,699,000Source |
| ProceedsFromIssuingSharesUSD | 6,255,000Source | — | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 4,861,000Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| Total RevenueUSD | 1,306,000Source | 2,879,000Source | 1,347,000Source | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | 26.94Source | 14.43Source | — | 2.83Source |
| DilutedEarningsLossPerShareUSD per share | 26.94Source | 14.43Source | — | — |
| EmployeeBenefitsExpenseUSD | 106,000Source | 105,000Source | 115,000Source | 98,000Source |
| FinanceCostsUSD | 353,000Source | 1,055,000Source | 2,014,000Source | 21,000Source |
| FinanceIncomeUSD | 612,000Source | 2,219,000Source | 7,832,000Source | — |
| GeneralAndAdministrativeExpenseUSD | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| GrossProfitUSD | 506,000Source | 2,196,000Source | 1,025,000Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | 1,344,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | -14,000Source | 22,000Source | 14,000Source | — |
| OtherIncomeUSD | 1,270,000Source | — | — | — |
| OtherOperatingIncomeExpenseUSD | — | — | -109,000Source | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -1,188,000Source | -761,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | -6,284,000Source | -5,122,000Source | 2,592,000Source | 5,789,000Source |
| ProfitLossBeforeTaxUSD | -7,486,000Source | -5,861,000Source | -2,578,000Source | — |
| ProfitLossFromOperatingActivitiesUSD | -7,316,000Source | -6,815,000Source | -8,287,000Source | -5,768,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,707,000Source | 1,641,000Source | 2,803,000Source | 1,990,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -429,000Source | -210,000Source | -109,000Source | — |
Filing attachments
ea030637702ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciS…
Read attachment ↗